Clenbuterol and the two-week myth

What a 34-hour half-life actually implies Mixed

Almost every discussion of clenbuterol quotes the half-life and then never uses it. It is the most informative number available, so start there. Our pharmacokinetic database carries 1.42 days, or about 34 hours, with a time to peak near 2.6 hours. Three consequences follow directly.

It accumulates. When you dose more often than the half-life, each dose lands on top of what is left of the last one. At once daily against a 34-hour half-life the accumulation ratio works out at about 2.6, so at plateau you are carrying roughly two and a half times the amount a single dose would give you. Someone who feels little on day one and increases the dose on day two is reacting to a curve that had not finished rising.

It plateaus around day six. Levels stop climbing at roughly 4.3 half-lives, which lands just past six days. Everything before that is still on the way up on an unchanged dose.

It clears in about a week. Five half-lives is the usual working definition of cleared, so a bit over seven days after the last dose. You can watch all three on the half-life calculator with clenbuterol already selected, which is a faster way to see the shape than reading about it.

Now the provenance, because it is better than this compound's reputation suggests. The figure does come from humans. Yamamoto and colleagues gave healthy volunteers 20, 40 and 80 mcg orally in 1985 and measured a plasma half-life of about 35 hours, with biphasic elimination: a short phase near an hour plus a long terminal phase. Rats in the same study ran near 30 hours. It is one small study using an enzyme immunoassay rather than the modern mass-spectrometry work behind the testosterone esters, which is why our database grades the evidence moderate rather than strong. It is measured human data all the same. One caveat on the plateau figure above: that same repeat-dose study observed plasma levels reaching plateau within about four days on twice-daily dosing, so the modelled six-day figure runs slightly ahead of the only measured one.

Where two on, two off came from Mixed

The schedule has a stated rationale, which is more than most bodybuilding conventions can claim. Clenbuterol works at the beta2 adrenoceptor. Beta2 receptors desensitize under sustained agonist exposure. So the reasoning goes: run it for two weeks, stop for two weeks to let the receptors recover, repeat. Tidy, mechanistic and wrong in both halves.

The off block is too long. Clearance takes about seven days. Whatever the second week is achieving, it is not removing drug, because there is none left to remove. It could in principle be resensitization time, except nobody has established how long beta2 resensitization takes in human skeletal muscle after clenbuterol, so the second week is a guess wearing the clothes of a protocol.

The on block is already too long. This is the part the 2025 evidence settles. Hostrup and colleagues ran 11 healthy men through two 14-day cycles of oral clenbuterol against placebo in a crossover design, with a three-week washout between arms, then measured beta2 adrenergic signalling in skeletal muscle. Tolerance was already established by the end of the two weeks. The desensitization the schedule exists to outrun happens inside the window the schedule allows for it.

Put the two together and the convention collapses. The first six days of every on block are spent climbing to a level the second week finally holds, that second week is where tolerance sets in, then half the off block does nothing. It is a round number that became a rule. There is a defensible general principle underneath it, that continuous beta2 agonism loses effect, but two and two is not what the principle implies.

To be explicit, because the obvious inference is the wrong one: none of this is an argument for a shorter break or a longer run. The tolerance finding says the drug stops doing what it did partway through the block, so the schedule is not the fixable part.

There is a behavioral trap folded into this. What fades first is the acute adrenergic response: the tremor, the racing heart, the jitters. People read fading side effects as the drug wearing off and increase the dose. What actually faded was the signal that the dose was substantial, on a curve that is still accumulating.

Does it do anything in a human? Mixed

Clenbuterol's reputation was built in rodents, where it is genuinely dramatic. Rat studies report skeletal muscle weight increases in the range of 19 to 39% depending on age. Numbers like that are why a veterinary bronchodilator became a physique drug.

Humans get something real and much smaller. In that same 2025 crossover trial, two weeks produced a 0.91 kg lean mass gain over placebo, accompanied by a 17% increase in skeletal muscle protein content measured on freeze-dried tissue rather than inferred from scale weight. With eleven men the confidence interval runs from 0.02 to 1.81 kg, so it is real while barely clear of nothing, plus a different order of magnitude from the animal work. Anyone whose expectations were set by the rodent literature is going to be disappointed by their own body.

The same trial recorded the other side of the ledger in the same two weeks: cardiorespiratory fitness fell and muscle oxidative capacity was repressed. A companion trial from the same group gave trained men high-dose oral salbutamol for eleven weeks alongside resistance training. It found larger lean mass gains plus thicker ventricular walls on echocardiography, though cardiac MRI in the same men found no change in left ventricular mass, so that remodeling finding is unsettled. The clenbuterol trial looked for the same thing across its two weeks and found no change in left ventricular mass either. So the honest summary is that it works, the documented cost inside a fortnight is aerobic rather than structural, then it stops working within that same fortnight.

What the toxicity literature shows Strong evidence

Unusually for this category, the harms are documented in the clinical literature rather than inferred, because clenbuterol keeps poisoning people who never intended to take it.

In 2005 the CDC reported an outbreak of 26 poisoning cases among heroin users whose supply had been adulterated with clenbuterol. The presentation was consistent: tachycardia, palpitations, chest pain, agitation plus hypokalemia. Twenty-four of the twenty-six were hospitalized, several in intensive care, with the reported cases running to around five days of fluids, potassium replacement and rate control. In a separate series of 34 presentations, six patients showed biochemical evidence of myocardial injury. A separate case series described a neuromuscular syndrome in five users, with muscle spasm, tremor, hyperreflexia plus raised creatine phosphokinase, though those authors noted the patients lacked the usual signs of acute clenbuterol toxicity so a second adulterant could not be ruled out. Contaminated meat has produced collective food poisoning where symptoms began within hours of a meal.

These are emergency-department symptoms, not ride-it-out symptoms. Chest pain, a racing or irregular heartbeat that will not settle, severe cramping or muscle weakness, or vomiting after a dose. In the documented outbreaks potassium fell as low as 1.9 mmol/L plus several patients showed blood-test evidence of heart muscle injury. Presenting early is what those patients got right.

Two things are worth taking from that. The potassium shift is real and it is the most plausible explanation for the cramps everyone attributes to something else. And the unit matters: clenbuterol is dosed in micrograms, not milligrams. The gap between an intended dose and a hospitalizing one is small enough that mislabeled product is a genuine hazard rather than a theoretical one. Any source that lists clenbuterol doses in milligrams is telling you something about the source.

The ECA stack and what the aspirin is for Mixed

Ephedrine, caffeine and aspirin sits in a strange position: better evidenced than almost anything else in this category, yet much less impressive than its reputation.

The 2003 JAMA meta-analysis pooled the trials and is still the best single answer. Ephedrine produced about 0.6 kg a month more weight loss than placebo. Ephedrine with caffeine reached roughly 1.0 kg a month. Ephedra with caffeine-containing herbs landed in the same place. The safety data across 50 trials showed 2.2 to 3.6-fold increased odds of psychiatric, autonomic or gastrointestinal symptoms and heart palpitations. No trial ran beyond six months, so the long-term column is empty rather than reassuring. Notably, the same review found no trials at all of ephedra and athletic performance. The seven ephedrine performance trials were too heterogeneous to pool.

The aspirin is the part nobody can justify cleanly. The proposed mechanism is that inhibiting prostaglandin synthesis blunts the feedback that desensitizes the response to ephedrine, prolonging the norepinephrine effect. It is plausible plus its practical contribution is debated, which is the whole of the case for dropping it. That matters because aspirin is the component with a daily cost attached. That cost is bleeding: gastrointestinal irritation and ulceration, plus reduced clotting for as long as you take it.

The competitor framing of an ECA-plus-steroid interaction deserves an honest answer rather than a dismissal. A daily antiplatelet layered on top of androgen-driven hypertension and a rising hematocrit is a coherent concern, though coherent rather than documented. No case series describes that specific syndrome. Treat it as a reason to know your blood pressure rather than as an established event.

Why detection is not clearance Strong evidence

Clenbuterol is prohibited at all times in sport, in the anabolic agents category rather than among the stimulants, which surprises people who think of it as a fat burner. Ephedrine is handled differently: prohibited in competition above a urine threshold rather than banned outright.

The important distinction is that a detection window and a clearance window answer different questions. Clearance is about how long the drug is doing something, which is roughly a week. Detection is about how little a laboratory can see. Modern assays see far below any concentration with an effect. The clearest evidence of that sensitivity is the meat-contamination problem: athletes have returned positives after eating meat from regions where clenbuterol is used illegally in livestock. Anti-doping science has put real work into telling contamination apart from deliberate use. A drug that can be detected from someone else's dinner is not a drug with a short detection window.

If you are running compounds alongside it, the cycle calculator covers what stacks with what. The bloodwork guide covers the panel. Potassium is the one worth adding here specifically, given what the poisoning literature shows about where it goes.